Cilostazol NDC 62135-986

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-986Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0986Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-986-60	62135098660	60 TABLET in 1 BOTTLE (62135-986-60)Marketed from Aug 27, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cilostazol
Generic name (nonproprietary): cilostazol
Active ingredients: Cilostazol — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077021
Marketing start: Nov 23, 2004
Listing expires: Dec 31, 2026
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 62135-986_3dfa32ae-94ba-4885-e063-6394a90a9333SPL ID 3dfa32ae-94ba-4885-e063-6394a90a9333SPL set ID 77e77eaf-5556-43ac-844e-c0e29f02fe07RxCUI 242461, 242462UNII N7Z035406BUPC 0362135986605, 0362135983604
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135098660 followed by a unit qualifier and the quantity

Package 62135-0986-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 4, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol tablets are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)